Ulnar osteosarcoma in dogs: 30 cases (1992–2008)

Ramesh K. Sivacolundhu Department of Surgery, Animal Medical Center, 510 E 62nd St, New York, NY 10065
Dr. Sivacolundhu's present address is Balcatta Veterinary Hospital, 59 Erindale Rd, Balcatta, WA 6021, Australia.

Search for other papers by Ramesh K. Sivacolundhu in
Current site
Google Scholar
PubMed
Close
 BVMS, MVS
,
Jeffrey J. Runge Department of Small Animal Surgery, Ryan Veterinary Hospital, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA 19104

Search for other papers by Jeffrey J. Runge in
Current site
Google Scholar
PubMed
Close
 DVM, DACVS
,
Taryn A. Donovan Department of Pathology, Animal Medical Center, 510 E 62nd St, New York, NY 10065

Search for other papers by Taryn A. Donovan in
Current site
Google Scholar
PubMed
Close
 DVM, DACVP
,
Lisa G. Barber Department of Clinical Sciences, Cummings School of Veterinary Medicine, Tufts University, Walpole, MA 02081

Search for other papers by Lisa G. Barber in
Current site
Google Scholar
PubMed
Close
 DVM, DACVIM
,
Corey F. Saba Department of Small Animal Medicine and Surgery, College of Veterinary Medicine, University of Georgia, Athens, GA 30602

Search for other papers by Corey F. Saba in
Current site
Google Scholar
PubMed
Close
 DVM, DACVIM
,
Craig A. Clifford Red Bank Veterinary Hospital, 197 Hance Ave, Tinton Falls, NJ 07724
Dr. Clifford's present address is Hope Veterinary Specialists, 40 3 Tun Rd, Malvern, PA 19355.

Search for other papers by Craig A. Clifford in
Current site
Google Scholar
PubMed
Close
 MS, DVM, DACVIM
,
Louis-Philippe de Lorimier Hôpital Vétérinaire Rive-Sud, 7415 Blvd Taschereau, Brossard, QC J4Y 1A2, Canada

Search for other papers by Louis-Philippe de Lorimier in
Current site
Google Scholar
PubMed
Close
 DVM, DACVIM
,
Stephen W. Atwater East Bay Veterinary Specialists and Emergency, 2803 Ygnacio Valley Rd, Walnut Creek, CA 94598

Search for other papers by Stephen W. Atwater in
Current site
Google Scholar
PubMed
Close
 DVM, MS, DACVIM
,
Lisa DiBernardi Veterinary Specialists of South Florida, 9410 Stirling Rd, Cooper City, FL 33024
Dr. DiBernardi's present address is Animal Specialty Hospital of Florida, 10130 Market St, Ste 1, Naples, FL 34112.

Search for other papers by Lisa DiBernardi in
Current site
Google Scholar
PubMed
Close
 DVM, DACVIM, DACVR
,
Kim P. Freeman Northwest Veterinary Specialists, 16756 SE 82nd Dr, Clackamas, OR 97015
Dr. Freeman's present address is Veterinary Cancer Referral Center, 1945 NW Pettygrove, Portland, OR 97209.

Search for other papers by Kim P. Freeman in
Current site
Google Scholar
PubMed
Close
 DVM, DACVIM
, and
Philip J. Bergman Katonah Bedford Veterinary Center, 546 N Bedford Rd (Rte 117), Bedford Hills, NY 10507

Search for other papers by Philip J. Bergman in
Current site
Google Scholar
PubMed
Close
 DVM, PhD, DACVIM

Abstract

Objective—To examine the biological behavior of ulnar osteosarcoma and evaluate predictors of survival time in dogs.

Design—Retrospective case series.

Animals—30 dogs with primary ulnar osteosarcoma.

Procedures—Medical records were reviewed. Variables recorded and examined to identify predictors of survival time were signalment, tumor location in the ulna, tumor length, serum alkaline phosphatase activity, surgery type, completeness of excision, tumor stage, tumor grade, histologic subtype, development of metastases, and use of chemotherapy.

Results—30 cases were identified from 9 institutions. Eleven dogs were treated with partial ulnar ostectomy and 14 with amputation; in 5 dogs, a resection was not performed. Twenty-two dogs received chemotherapy. Median disease-free interval and survival time were 437 and 463 days, respectively. Negative prognostic factors for survival time determined via univariate analyses were histologic subtype and development of lung metastases. Telangiectatic or telangiectatic-mixed subtype (n = 5) was the only negative prognostic factor identified via multivariate analysis (median survival time, 208 days). Dogs with telangiectatic subtype were 6.99 times as likely to die of the disease.

Conclusions and Clinical Relevance—The prognosis for ulnar osteosarcoma in this population was no worse and may have been better than the prognosis for dogs with osteosarcoma involving other appendicular sites. Partial ulnar ostectomy was associated with a low complication rate and good to excellent function and did not compromise survival time. Telangiectatic or telangiectatic-mixed histologic subtype was a negative prognostic factor for survival time. The efficacy of chemotherapy requires further evaluation.

Abstract

Objective—To examine the biological behavior of ulnar osteosarcoma and evaluate predictors of survival time in dogs.

Design—Retrospective case series.

Animals—30 dogs with primary ulnar osteosarcoma.

Procedures—Medical records were reviewed. Variables recorded and examined to identify predictors of survival time were signalment, tumor location in the ulna, tumor length, serum alkaline phosphatase activity, surgery type, completeness of excision, tumor stage, tumor grade, histologic subtype, development of metastases, and use of chemotherapy.

Results—30 cases were identified from 9 institutions. Eleven dogs were treated with partial ulnar ostectomy and 14 with amputation; in 5 dogs, a resection was not performed. Twenty-two dogs received chemotherapy. Median disease-free interval and survival time were 437 and 463 days, respectively. Negative prognostic factors for survival time determined via univariate analyses were histologic subtype and development of lung metastases. Telangiectatic or telangiectatic-mixed subtype (n = 5) was the only negative prognostic factor identified via multivariate analysis (median survival time, 208 days). Dogs with telangiectatic subtype were 6.99 times as likely to die of the disease.

Conclusions and Clinical Relevance—The prognosis for ulnar osteosarcoma in this population was no worse and may have been better than the prognosis for dogs with osteosarcoma involving other appendicular sites. Partial ulnar ostectomy was associated with a low complication rate and good to excellent function and did not compromise survival time. Telangiectatic or telangiectatic-mixed histologic subtype was a negative prognostic factor for survival time. The efficacy of chemotherapy requires further evaluation.

All Time Past Year Past 30 Days
Abstract Views 379 0 0
Full Text Views 2199 1112 95
PDF Downloads 1152 457 38
Advertisement